The role of antihypertensive drugs in Covid-19
- Funded by FWF
- Total publications:244 publications
Grant number: Unknown
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$428,400Funder
FWFPrincipal Investigator
. Oliver LangerResearch Location
AustriaLead Research Institution
Department of Clinical Pharmacology, Medical University of ViennaResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Do antihypertensive drugs have an impact on SARS-CoV-2 infection? Since the pandemic began, researchers have been using a variety of methods in an attempt to definitively determine the role of the ACE2 enzyme, but so far without success. This enzyme is of interest because it allows the coronavirus to enter and infect healthy cells. Pharmacist Oliver Langer and his group plan to use the FWF urgent funding to develop a method that can determine the concentration of ACE2 in tissue using positron emission tomography (PET) with a radiolabelled substance, thus enabling us to better assess the impact of antihypertensives. The method and the results derived from it will make an important contribution to the development of new COVID-19 drugs.
Publicationslinked via Europe PMC
Last Updated:9 days ago
View all publications at Europe PMC